瑞典新生儿表面活性剂最佳实践依从性与临床结局的关联
该研究基于瑞典2009–2018年97 377名新生儿的登记数据,分析表面活性剂使用(时机、次数、超说明书使用、漏用)与临床结局的关联。在22–31周早产儿中,38.9%首剂在出生2小时后给予,与气胸(aOR 2.59)、IVH 3–4级(aOR 1.71)等风险升高相关,但生存率也较高(aOR 1.45);漏用表面活性剂(5.7%)与生存率降低相关(aOR 0.49)。结论提示表面活性剂最佳实践依从性存在差异,对新生儿结局有重要临床意义。
要点
- 22–31周早产儿中,首剂表面活性剂在出生2小时后给予占38.9%,与气胸风险升高相关(aOR 2.59;95%CI 1.76–3.83)。
- 首剂延迟(>2小时)还与IVH 3–4级(aOR 1.71;95%CI 1.23–2.39)、产后激素使用(aOR 1.57;95%CI 1.22–2.03)及机械通气时间延长(aOR 1.34;95%CI 1.04–1.72)相关。
- 首剂延迟组生存率反而较高(aOR 1.45;95%CI 1.10–1.91),需注意混杂因素。
- 机械通气患儿中漏用表面活性剂占5.7%,与生存率降低相关(aOR 0.49;95%CI 0.30–0.82)。
- 超说明书使用(>3次)占2.8%,未显示结局改善;足月儿中53.4%使用表面活性剂者诊断为胎粪吸入综合征,使用未与结局改善相关。
适用人群与场景
- 2009–2018年瑞典出生的97 377名无畸形并接受新生儿监护的婴儿。
- 主要分析人群为胎龄<32周的极早产儿;表面活性剂使用者中胎龄分布:足月12.1%,32–36周13.3%,28–31周29.6%,<28周45.0%。
诊断标准与关键阈值
- 注册使用定义:按药品标签用于呼吸窘迫综合征(RDS)的1–3次给药。
- 漏用定义:因RDS接受机械通气但未给予表面活性剂。
- 首剂延迟阈值:出生后2小时。
研究设计与关键结果
- 研究类型:基于人群的队列研究,使用瑞典2009–2018年登记数据,纳入97 377名婴儿;数据分析时间为2019年6月至2020年6月。
- 共5209名婴儿接受7980次表面活性剂给药:女2233名(42.9%),男2976名(57.1%)。
- 超说明书使用977名(18.8%);超过推荐最多3次给药者146名(2.8%),未见结局改善。
- 22–31周婴儿中1364/3508名(38.9%)首剂在出生2小时后给予,与2小时内给药相比:气胸aOR 2.59(95%CI 1.76–3.83)、IVH 3–4级aOR 1.71(95%CI 1.23–2.39)、产后激素使用aOR 1.57(95%CI 1.22–2.03)、辅助通气时间延长aOR 1.34(95%CI 1.04–1.72)、生存率较高aOR 1.45(95%CI 1.10–1.91)。
- 机械通气婴儿中漏用表面活性剂203/3551名(5.7%),与生存率降低相关(aOR 0.49;95%CI 0.30–0.82)。
- 足月儿中接受表面活性剂者336名(53.4%)诊断为胎粪吸入综合征;用于胎粪吸入未与新生儿结局改善相关。
证据类型、等级与局限
- 证据类型:基于人群的队列研究。
- 局限:原文未报告局限性。
对床旁实践的改变
- 该研究提示,22–31周早产儿首剂表面活性剂在出生2小时后给予与气胸、IVH 3–4级、产后激素使用及通气时间延长相关,漏用与生存率降低相关;作者认为表面活性剂最佳实践依从性差异对新生儿结局有重要临床意义。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
IMPORTANCE: While surfactant therapy for respiratory distress syndrome (RDS) in preterm infants has been evaluated in clinical trials, less is known about how surfactant is used outside such a framework.
OBJECTIVE: To evaluate registered use, off-label use, and omissions of surfactant treatment by gestational age (GA) and associations with outcomes, mainly among very preterm infants (GA <32 weeks).
DESIGN, SETTING, AND PARTICIPANTS: This population-based cohort study used registry data for 97 377 infants born in Sweden between 2009 and 2018. Infants did not have malformations and were admitted for neonatal care. Data analysis was conducted from June 2019 to June 2020.
EXPOSURES: Timing and number of surfactant administrations, off-label use, and omission of use. Registered use was defined by drug label (1-3 administrations for RDS). Omissions were defined as surfactant not administered despite mechanical ventilation for RDS.
MAIN OUTCOME AND MEASURES: In-hospital survival, pneumothorax, intraventricular hemorrhage grade 3 to 4, duration of mechanical ventilation, use of postnatal systemic corticosteroids for lung disease, treatment with supplemental oxygen at 28 days' postnatal age and at 36 weeks' postmenstrual age. Odds ratios (ORs) were calculated and adjusted for any prenatal corticosteroid treatment, cesarean delivery, GA, infant sex, Apgar score at 10 minutes, and birth weight z score of less than -2.
RESULTS: In total, 7980 surfactant administrations were given to 5209 infants (2233 [42.9%] girls; 2976 [57.1%] boys): 629 (12.1%) born at full term, 691 (13.3%) at 32 to 36 weeks' GA, 1544 (29.6%) at 28 to 31 weeks' GA, and 2345 (45.0%) at less than 28 weeks' GA. Overall, 977 infants (18.8%) received off-label use. In 1364 of 3508 infants (38.9%) with GA of 22 to 31 weeks, the first administration of surfactant was given more than 2 hours after birth, and this was associated with higher odds of pneumothorax (adjusted OR [aOR], 2.59; 95% CI, 1.76-3.83), intraventricular hemorrhage grades 3 to 4 (aOR, 1.71; 95% CI, 1.23-2.39), receipt of postnatal corticosteroids (aOR, 1.57; 95% CI, 1.22-2.03), and longer duration of assisted ventilation (aOR, 1.34; 95% CI, 1.04-1.72) but also higher survival (aOR, 1.45; 95% CI, 1.10-1.91) than among infants treated within 2 hours of birth. In 146 infants (2.8%), the recommended maximum of 3 surfactant administrations was exceeded but without associated improvements in outcome. Omission of surfactant treatment occurred in 203 of 3551 infants (5.7%) who were receiving mechanical ventilation and was associated with lower survival (aOR, 0.49; 95% CI, 0.30-0.82). In full-term infants, 336 (53.4%) of those receiving surfactant had a diagnosis of meconium aspiration syndrome. Surfactant for meconium aspiration was not associated with improved neonatal outcomes.
CONCLUSIONS AND RELEVANCE: In this study, adherence to best practices and labels for surfactant use in newborn infants varied, with important clinical implications for neonatal outcomes.
参考来源
- Challis P, Nydert P, Håkansson S, et al. Association of Adherence to Surfactant Best Practice Uses With Clinical Outcomes Among Neonates in Sweden. JAMA Netw Open. 2021. PMID: 33950208. doi:10.1001/jamanetworkopen.2021.7269
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。